AnaptysBio Secures Delaware Court Dismissal in GSK Case
ANAB has more than doubled off its 52-week low of $11.402.
Summary
The Delaware Chancery Court has granted a motion to dismiss filed by AnaptysBio, resolving a legal matter involving GSK in the company's favor. This positive legal outcome follows a similar decision on April 24, where the same court dismissed an anticipatory breach claim brought by Tesaro against AnaptysBio. The repeated success in the Delaware Chancery Court suggests a strong legal position for AnaptysBio and removes a potential legal overhang, which is a material positive for the company. Investors will watch for further details on the specific nature of the dismissed claim and any remaining litigation.
At the time of this announcement, ANAB was trading at $59.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $11.40 to $60.60. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.